Provided by Tiger Trade Technology Pte. Ltd.

EyePoint

4.11
-0.2300-5.30%
Volume:863.00K
Turnover:3.68M
Market Cap:354.33M
PE:-1.09
High:4.40
Open:4.32
Low:4.11
Close:4.34
52wk High:19.11
52wk Low:3.95
Shares:86.21M
Float Shares:60.67M
Volume Ratio:1.81
T/O Rate:1.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7642
EPS(LYR):-3.1667
ROE:-148.70%
ROA:-74.85%
PB:2.13
PE(LYR):-1.30

Loading ...

EyePoint Inc : JP Morgan Cuts to Neutral from Overweight

THOMSON REUTERS
·
Aug 18

EyePoint downgraded to Sector Perform from Outperform at RBC Capital

TIPRANKS
·
Aug 18

NASD Most Active Issues

Dow Jones
·
Aug 18

Mobile Healthcare Provider DocGo's Q2 Revenue Misses on Wind-Down of Migrant Programs

Reuters
·
Aug 18

U.S. Small Caps Drop; EyePoint Posts Biggest Loss

Dow Jones
·
Aug 18

Laidlaw trims EyePoint target, still sees high change of approval

TIPRANKS
·
Aug 18

Top Midday Decliners

MT Newswires Live
·
Aug 18

B. Riley views EyePoint study miss as positive for 4D Molecular

TIPRANKS
·
Aug 18

EyePoint price target lowered to $8 from $30 at Jefferies

TIPRANKS
·
Aug 18

JPMorgan Downgrades EyePoint Pharmaceuticals to Neutral From Overweight

MT Newswires Live
·
Aug 17

EyePoint downgraded to Neutral from Overweight at JPMorgan

TIPRANKS
·
Aug 17

U.S. Stocks on the MOVE - Sunrun, JetBlue Airways, Dell Technologies

Reuters
·
Aug 17

Top Midday Stories: Nvidia Investing $1.5 Billion in SB Energy; L3Harris Names Sam Mehta as CEO, Replacing Christopher Kubasik

MT Newswires Live
·
Aug 17

EyePoint Stock Craters 71% After Drug Trial Failure. it May be an Overreaction.

Dow Jones
·
Aug 17

EyePoint Down over 70%, on Pace for Record Percent Decrease

Dow Jones
·
Aug 17

EyePoint Reports Pivotal Phase 3 LUGANO Trial Results

TIPRANKS
·
Aug 17

Rival Ocular Therapeutix Shares up 8%

THOMSON REUTERS
·
Aug 17

Morning Movers: EyePoint plummets following LUGANO trial results

TIPRANKS
·
Aug 17

EyePoint is Maintained at Buy by Chardan Capital

Dow Jones
·
Aug 17

EyePoint Tumbles After Experimental Eye Drug Misses Main Goal in Late-Stage Study

Reuters
·
Aug 17